ICOS-Fc as innovative immunomodulatory approach to counteract inflammation and organ injury in sepsis.
Animals
Male
Mice
Creatinine
Cytokines
/ metabolism
Immune Checkpoint Proteins
Immunity
Immunomodulation
Inducible T-Cell Co-Stimulator Ligand
/ genetics
Inducible T-Cell Co-Stimulator Protein
/ genetics
Inflammasomes
Inflammation
Interleukin-10
Interleukin-6
Ligands
Mice, Inbred C57BL
Mice, Knockout
NLR Family, Pyrin Domain-Containing 3 Protein
Osteopontin
p38 Mitogen-Activated Protein Kinases
Sepsis
/ drug therapy
Tumor Necrosis Factor-alpha
Urea
ICOS (inducible co-stimulatory molecule)
cecal ligation and puncture
inflammation
osteopontin (OPN)
sepsis
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
07
2022
accepted:
08
08
2022
entrez:
19
9
2022
pubmed:
20
9
2022
medline:
21
9
2022
Statut:
epublish
Résumé
Inducible T cell co-stimulator (ICOS), an immune checkpoint protein expressed on activated T cells and its unique ligand, ICOSL, which is expressed on antigen-presenting cells and non-hematopoietic cells, have been extensively investigated in the immune response. Recent findings showed that a soluble recombinant form of ICOS (ICOS-Fc) can act as an innovative immunomodulatory drug as both antagonist of ICOS and agonist of ICOSL, modulating cytokine release and cell migration to inflamed tissues. Although the ICOS-ICOSL pathway has been poorly investigated in the septic context, a few studies have reported that septic patients have reduced ICOS expression in whole blood and increased serum levels of osteopontin (OPN), that is another ligand of ICOSL. Thus, we investigated the pathological role of the ICOS-ICOSL axis in the context of sepsis and the potential protective effects of its immunomodulation by administering ICOS-Fc in a murine model of sepsis. Polymicrobial sepsis was induced by cecal ligation and puncture (CLP) in five-month-old male wild-type (WT) C57BL/6, ICOS
Identifiants
pubmed: 36119089
doi: 10.3389/fimmu.2022.992614
pmc: PMC9479331
doi:
Substances chimiques
Creatinine
AYI8EX34EU
Cytokines
0
Icos protein, mouse
0
Immune Checkpoint Proteins
0
Inducible T-Cell Co-Stimulator Ligand
0
Inducible T-Cell Co-Stimulator Protein
0
Inflammasomes
0
Interleukin-10
130068-27-8
Interleukin-6
0
Ligands
0
NLR Family, Pyrin Domain-Containing 3 Protein
0
Osteopontin
106441-73-0
p38 Mitogen-Activated Protein Kinases
EC 2.7.11.24
Tumor Necrosis Factor-alpha
0
Urea
8W8T17847W
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
992614Informations de copyright
Copyright © 2022 Alves, Stoppa, Aimaretti, Monge, Mastrocola, Porchietto, Einaudi, Collotta, Bertocchi, Boggio, Gigliotti, Clemente, Aragno, Fernandes, Cifani, Thiemermann, Dianzani, Dianzani and Collino.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Rev Immunol. 2013 Dec;13(12):862-74
pubmed: 24232462
J Thorac Dis. 2016 May;8(5):E312-6
pubmed: 27162689
J Clin Invest. 2019 Apr 1;129(4):1713-1726
pubmed: 30747722
Am J Physiol Heart Circ Physiol. 2020 Sep 1;319(3):H705-H721
pubmed: 32762560
Intensive Care Med Exp. 2018 Jul 27;6(1):20
pubmed: 30054760
Acta Anaesthesiol Scand. 2015 Feb;59(2):170-5
pubmed: 25328143
Eur J Pharmacol. 2017 Jul 15;807:174-181
pubmed: 28483456
Am J Physiol Renal Physiol. 2018 Oct 1;315(4):F759-F768
pubmed: 29717936
J Immunol. 2016 Nov 15;197(10):3905-3916
pubmed: 27798154
Nature. 1999 Jan 21;397(6716):263-6
pubmed: 9930702
J Immunol. 2014 May 15;192(10):4921-31
pubmed: 24729612
PLoS Biol. 2020 Jul 14;18(7):e3000410
pubmed: 32663219
Commun Biol. 2020 Oct 26;3(1):615
pubmed: 33106594
J Immunol. 2010 Oct 1;185(7):3970-9
pubmed: 20817864
Crit Care. 2011 Jul 28;15(4):R183
pubmed: 21798063
J Cell Commun Signal. 2009 Dec;3(3-4):311-22
pubmed: 19798593
Gastroenterology. 2008 Sep;135(3):980-8
pubmed: 18621049
Immunity. 1999 Oct;11(4):423-32
pubmed: 10549624
J Immunol. 2013 Feb 1;190(3):1125-34
pubmed: 23275603
Front Immunol. 2022 Feb 01;13:837180
pubmed: 35178052
J Immunol Res. 2016;2016:9345495
pubmed: 27478856
J Microbiol Immunol Infect. 2013 Oct;46(5):338-44
pubmed: 22921804
BMC Biotechnol. 2007 Aug 01;7:46
pubmed: 17678525
Shock. 2018 Oct;50(4):377-380
pubmed: 30106875
Nature. 1999 Dec 16;402(6763):827-32
pubmed: 10617205
Mol Med. 2018 Oct 17;24(1):54
pubmed: 30332984
Front Immunol. 2021 Dec 03;12:786680
pubmed: 34925367
Am J Respir Crit Care Med. 2017 Sep 15;196(6):713-726
pubmed: 28245134
Int J Mol Sci. 2022 Jul 01;23(13):
pubmed: 35806368
Dis Model Mech. 2013 May;6(3):701-9
pubmed: 23264564
J Clin Med. 2019 Sep 06;8(9):
pubmed: 31500177
Behav Res Methods. 2007 May;39(2):175-91
pubmed: 17695343
Lancet. 2020 Jan 18;395(10219):200-211
pubmed: 31954465
PLoS One. 2020 Jun 17;15(6):e0234039
pubmed: 32555710
Cytokine. 2017 Feb;90:88-95
pubmed: 27863335
Tohoku J Exp Med. 2008 Sep;216(1):61-8
pubmed: 18719339
JAMA. 2011 Dec 21;306(23):2594-605
pubmed: 22187279
Cell Death Dis. 2022 Jul 8;13(7):589
pubmed: 35803916
J Interferon Cytokine Res. 2015 Dec;35(12):969-80
pubmed: 26309018
Crit Care. 2015 Feb 26;19:53
pubmed: 25887405
Cells. 2019 Feb 18;8(2):
pubmed: 30781721
J Immunol. 2008 Jan 15;180(2):774-82
pubmed: 18178815
In Vivo. 2013 Nov-Dec;27(6):669-84
pubmed: 24292568
J Surg Res. 2009 Mar;152(1):46-53
pubmed: 19027920
Int J Med Sci. 2018 Apr 3;15(7):666-673
pubmed: 29910670
Sci Rep. 2016 Oct 31;6:36214
pubmed: 27796369